<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>44</viewCount><searchCount>0</searchCount></scores><additional><submitter>Yu J</submitter><funding>NCI NIH HHS</funding><pagination>2608-2614</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5670032</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(12)</volume><pubmed_abstract>Wnt5a can activate Rho GTPases in chronic lymphocytic leukemia (CLL) cells by inducing the recruitment of ARHGEF2 to ROR1. Mass spectrometry on immune precipitates of Wnt5a-activated ROR1 identified 14-3-3ζ, which was confirmed by co-immunoprecipitation. The capacity of Wnt5a to induce ROR1 to complex with 14-3-3ζ could be blocked in CLL cells by treatment with cirmtuzumab, a humanized mAb targeting ROR1. Silencing 14-3-3ζ via small interfering RNA impaired the capacity of Wnt5a to: (1) induce recruitment of ARHGEF2 to ROR1, (2) enhance in vitro exchange activity of ARHGEF2 and (3) induce activation of RhoA and Rac1 in CLL cells. Furthermore, CRISPR/Cas9 deletion of 14-3-3ζ in ROR1-negative CLL cell-line MEC1, and in MEC1 cells transfected to express ROR1 (MEC1-ROR1), demonstrated that 14-3-3ζ was necessary for the growth/engraftment advantage of MEC1-ROR1 over MEC1 cells. We identified a binding motif (RSPS&lt;sup>857&lt;/sup>SAS) in ROR1 for 14-3-3ζ. Site-directed mutagenesis of ROR1 demonstrated that serine-857 was required for the recruitment of 14-3-3ζ and ARHGEF2 to ROR1, and activation of RhoA and Rac1. Collectively, this study reveals that 14-3-3ζ plays a critical role in Wnt5a/ROR1 signaling, leading to enhanced CLL migration and proliferation.</pubmed_abstract><journal>Leukemia</journal><pubmed_title>Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.</pubmed_title><pmcid>PMC5670032</pmcid><funding_grant_id>P01 CA081534</funding_grant_id><pubmed_authors>Hasan MK</pubmed_authors><pubmed_authors>Shen Z</pubmed_authors><pubmed_authors>Kipps TJ</pubmed_authors><pubmed_authors>Rassenti LZ</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Widhopf GF</pubmed_authors><pubmed_authors>Ghia EM</pubmed_authors><pubmed_authors>Wu R</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Yu J</pubmed_authors><pubmed_authors>Briggs SP</pubmed_authors><view_count>44</view_count></additional><is_claimable>false</is_claimable><name>Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.</name><description>Wnt5a can activate Rho GTPases in chronic lymphocytic leukemia (CLL) cells by inducing the recruitment of ARHGEF2 to ROR1. Mass spectrometry on immune precipitates of Wnt5a-activated ROR1 identified 14-3-3ζ, which was confirmed by co-immunoprecipitation. The capacity of Wnt5a to induce ROR1 to complex with 14-3-3ζ could be blocked in CLL cells by treatment with cirmtuzumab, a humanized mAb targeting ROR1. Silencing 14-3-3ζ via small interfering RNA impaired the capacity of Wnt5a to: (1) induce recruitment of ARHGEF2 to ROR1, (2) enhance in vitro exchange activity of ARHGEF2 and (3) induce activation of RhoA and Rac1 in CLL cells. Furthermore, CRISPR/Cas9 deletion of 14-3-3ζ in ROR1-negative CLL cell-line MEC1, and in MEC1 cells transfected to express ROR1 (MEC1-ROR1), demonstrated that 14-3-3ζ was necessary for the growth/engraftment advantage of MEC1-ROR1 over MEC1 cells. We identified a binding motif (RSPS&lt;sup>857&lt;/sup>SAS) in ROR1 for 14-3-3ζ. Site-directed mutagenesis of ROR1 demonstrated that serine-857 was required for the recruitment of 14-3-3ζ and ARHGEF2 to ROR1, and activation of RhoA and Rac1. Collectively, this study reveals that 14-3-3ζ plays a critical role in Wnt5a/ROR1 signaling, leading to enhanced CLL migration and proliferation.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Dec</publication><modification>2024-02-15T02:35:51.622Z</modification><creation>2019-03-27T03:00:52Z</creation></dates><accession>S-EPMC5670032</accession><cross_references><pubmed>28465528</pubmed><doi>10.1038/leu.2017.132</doi></cross_references></HashMap>